drugset

drugset / Trial / NCT03425279

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

NCT03425279 ↗

Phase 1/2 Completed 245 enrolled BioAtla, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.

Timeline

Start: 2018-02-15
Primary completion: 2025-01-08
Completion: 2025-01-08

Publications

Hoff CO, Dal Lago EA, Siqueira JM, de Sousa LG, El-Naggar AK, Ahnert JR, Ferrarotto R. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO Precis Oncol. 2024 Apr;8:e2300633. doi: 10.1200/PO.23.00633.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mecbotamab vedotin	Unknown	—	—

Indications